mAbxience and Amneal Announce FDA Approval of Denosumab Biosimilars Referencing Prolia® and XGEVA®Miguel Martínez-Cava2025-12-22T22:02:19+01:00December 22, 2025|Press releases|
mAbxience and HP drive the use of artificial intelligence in biomanufacturing and biosimilar developmentMiguel Martínez-Cava2025-12-17T10:19:49+01:00December 4, 2025|Press releases|
mAbxience announces European Commission approval of denosumab biosimilarsadriana.polo2025-07-02T15:00:56+02:00July 2, 2025|Press releases|
How are biosimilars developed? From cell lines to commercial batchD3v3l0P_3C2026-08-28T16:56:48+02:00August 28, 2026|News|
Why oncology biosimilars require a different level of readinessD3v3l0P_3C2026-08-28T16:50:18+02:00August 28, 2026|News|
Common tech transfer risks in biologics and how CDMOs help reduce themD3v3l0P_3C2026-08-28T16:43:18+02:00August 28, 2026|News|